Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Therapeutic Prospects for Th-17 Cell Immune Storm Syndrome and Neurological Symptoms in COVID-19: Thiamine Efficacy and Safety, In-vitro Evidence and Pharmacokinetic Profile

View ORCID ProfileVatsalya Vatsalya, Fengyuan Li, Jane Frimodig, View ORCID ProfileKhushboo S. Gala, Shweta Srivastava, Maiying Kong, Vijay A Ramchandani, Wenke Feng, Xiang Zhang, Craig J McClain
doi: https://doi.org/10.1101/2020.08.23.20177501
Vatsalya Vatsalya
1Department of Medicine, University of Louisville, Louisville, KY USA
2Robley Rex VA Medical Center, Louisville, KY USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Vatsalya Vatsalya
  • For correspondence: v0vats01@louisville.edu
Fengyuan Li
1Department of Medicine, University of Louisville, Louisville, KY USA
3University of Louisville Alcohol Research Center, Louisville, KY USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jane Frimodig
1Department of Medicine, University of Louisville, Louisville, KY USA
2Robley Rex VA Medical Center, Louisville, KY USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Khushboo S. Gala
1Department of Medicine, University of Louisville, Louisville, KY USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Khushboo S. Gala
Shweta Srivastava
1Department of Medicine, University of Louisville, Louisville, KY USA
4Envirome Institute, University of Louisville, Louisville, KY USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maiying Kong
2Robley Rex VA Medical Center, Louisville, KY USA
5Department of Bioinformatics and Biostatistics, University of Louisville, Louisville, KY USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vijay A Ramchandani
6National Institute on Alcohol Abuse and Alcoholism, NIH, Bethesda, MD USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wenke Feng
1Department of Medicine, University of Louisville, Louisville, KY USA
3University of Louisville Alcohol Research Center, Louisville, KY USA
7Department of Pharmacology and Toxicology, University of Louisville, Louisville, KY USA
10University of Louisville Hepatobiology & Toxicology COBRE, Louisville, KY USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiang Zhang
3University of Louisville Alcohol Research Center, Louisville, KY USA
7Department of Pharmacology and Toxicology, University of Louisville, Louisville, KY USA
8Department of Chemistry, University of Louisville, Louisville, KY USA
9Center for Regulatory and Environmental Analytical Metabolomics, University of Louisville, Louisville, KY USA
10University of Louisville Hepatobiology & Toxicology COBRE, Louisville, KY USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Craig J McClain
1Department of Medicine, University of Louisville, Louisville, KY USA
2Robley Rex VA Medical Center, Louisville, KY USA
3University of Louisville Alcohol Research Center, Louisville, KY USA
7Department of Pharmacology and Toxicology, University of Louisville, Louisville, KY USA
10University of Louisville Hepatobiology & Toxicology COBRE, Louisville, KY USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Introduction Emerging infectious diseases, especially the coronavirus disease identified in 2019 (COVID-19), can be complicated by a severe exacerbation in the Th17 cell-mediated IL-17 proinflammatory immune storm. This enhanced immune response plays a major role in mortality and morbidity, including neurological symptoms. We hypothesized that countering the cytokine storm with thiamine may have therapeutic efficacy in lowering the Th17 cell proinflammatory response. We used an in vitro study and corroborated those results in disease controls (DC). We developed an effective dose range and model for key pharmacokinetic measures with the potential of targeting the cytokine storm and neurological symptoms of COVID-19.

Study Participants and Methods We investigated the effect of a three-week 200 mg dose of thiamine in lowering the Th17 response in sixteen DC (proinflammatory origin due to heavy alcohol drinking) patients; and eight healthy control/volunteers (HV) as a pilot clinical-translational investigation. To further investigate, we performed an in vitro study evaluating the effectiveness of thiamine treatment in lowering the Th17 proinflammatory response in a mouse macrophage cell line (RAW264.7) treated with ethanol. In this in vitro study, 100 mg/day equivalent (0.01 µg/ml) thiamine was used. Based on recent publications, we compared the results of the IL-17 response from our clinical and in vitro study to those found in other proinflammatory disease conditions (metabolic conditions, septic shock, viral infections and COVID-19), including symptoms, and dose ranges of effective and safe administration of thiamine. We developed a dose range and pharmacokinetic profile for thiamine as a novel intervention strategy in COVID-19 to alleviate the effects of the cytokine storm and neurological symptoms.

Results The DC group showed significantly elevated proinflammatory cytokines compared to HV. Three-week of 200 mg daily thiamine treatment significantly lowered the baseline IL-17 levels while increased IL-22 levels (anti-inflammatory response). This was validated by an in vitro macrophage response using a lower thiamine dose equivalent (100 mg), which resulted in attenuation of IL-17 and elevation of IL-22 at the mRNA level compared to the ethanol-only treated group. In humans, a range of 79-474 mg daily of thiamine was estimated to be effective and safe as an intervention for the COVID-19 cytokine storm. A literature review showed that several neurological symptoms of COVID-19 (which exist in 45.5% of the severe cases) occur in other viral infections and neuroinflammatory states that may also respond to thiamine treatment.

Discussion The Th17 mediated IL-17 proinflammatory response can potentially be attenuated by thiamine. Thiamine, a very safe drug even at very high doses, could be repurposed for treating the cytokine/immune storm of COVID-19 and the subsequent neurological symptoms observed in COVID-19 patients. Further studies using thiamine as an interventional/prevention strategy in severe COVID-19 patients could identify its precise anti-inflammatory role.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

NCT# 01809132 and 00106106

Funding Statement

Study was supported by NIH: NIH-OD-OHSRP-12176 (VV), R15CA170091-01A1 (MK), ZIA AA000466 (VAR), R01AA023190 (WF), P50AA024337-8301 and P20GM113226-6169 (XZ), and P50AA024337, P20GM113226, U01AA026936, U01AA0279880, R01AA023681 (CJM). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Study was approved by the Institutional Review Boards of all the sites. All patients and healthy volunteers included in this study consented to participate before the beginning of the study.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Conflicts of Interest: All authors declare no conflict of interests.

  • Proprietorship: This article is a work of the University of Louisville Alcohol Research Center and National Institutes of Health. This manuscript is in the public domain in the USA. Email address for the readers to contact the author to obtain the data: v0vats01{at}louisville.edu.

  • Project/Grant Support: Study was supported by NIH: NIH-OD-OHSRP-12176 (VV), R15CA170091-01A1 (MK), ZIA AA000466 (VAR), R01AA023190 (WF), P50AA024337-8301 and P20GM113226-6169 (XZ), and P50AA024337, P20GM113226, U01AA026936, U01AA0279880, R01AA023681 (CJM). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Data Availability

The datasets analyzed during the current study are available from the corresponding author by request.

  • Abbreviations

    COVID-19
    Coronavirus Disease-19
    IL-17
    Interleukin 17
    IL-22
    Interleukin 22
    Disease Controls
    (DC)
    HV
    Healthy Volunteers
  • Copyright 
    The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
    Back to top
    PreviousNext
    Posted August 25, 2020.
    Download PDF

    Supplementary Material

    Data/Code
    Email

    Thank you for your interest in spreading the word about medRxiv.

    NOTE: Your email address is requested solely to identify you as the sender of this article.

    Enter multiple addresses on separate lines or separate them with commas.
    Therapeutic Prospects for Th-17 Cell Immune Storm Syndrome and Neurological Symptoms in COVID-19: Thiamine Efficacy and Safety, In-vitro Evidence and Pharmacokinetic Profile
    (Your Name) has forwarded a page to you from medRxiv
    (Your Name) thought you would like to see this page from the medRxiv website.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Share
    Therapeutic Prospects for Th-17 Cell Immune Storm Syndrome and Neurological Symptoms in COVID-19: Thiamine Efficacy and Safety, In-vitro Evidence and Pharmacokinetic Profile
    Vatsalya Vatsalya, Fengyuan Li, Jane Frimodig, Khushboo S. Gala, Shweta Srivastava, Maiying Kong, Vijay A Ramchandani, Wenke Feng, Xiang Zhang, Craig J McClain
    medRxiv 2020.08.23.20177501; doi: https://doi.org/10.1101/2020.08.23.20177501
    Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
    Citation Tools
    Therapeutic Prospects for Th-17 Cell Immune Storm Syndrome and Neurological Symptoms in COVID-19: Thiamine Efficacy and Safety, In-vitro Evidence and Pharmacokinetic Profile
    Vatsalya Vatsalya, Fengyuan Li, Jane Frimodig, Khushboo S. Gala, Shweta Srivastava, Maiying Kong, Vijay A Ramchandani, Wenke Feng, Xiang Zhang, Craig J McClain
    medRxiv 2020.08.23.20177501; doi: https://doi.org/10.1101/2020.08.23.20177501

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Subject Area

    • Infectious Diseases (except HIV/AIDS)
    Subject Areas
    All Articles
    • Addiction Medicine (216)
    • Allergy and Immunology (495)
    • Anesthesia (106)
    • Cardiovascular Medicine (1099)
    • Dentistry and Oral Medicine (196)
    • Dermatology (141)
    • Emergency Medicine (274)
    • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (502)
    • Epidemiology (9781)
    • Forensic Medicine (5)
    • Gastroenterology (481)
    • Genetic and Genomic Medicine (2317)
    • Geriatric Medicine (223)
    • Health Economics (462)
    • Health Informatics (1563)
    • Health Policy (737)
    • Health Systems and Quality Improvement (606)
    • Hematology (238)
    • HIV/AIDS (506)
    • Infectious Diseases (except HIV/AIDS) (11655)
    • Intensive Care and Critical Care Medicine (617)
    • Medical Education (239)
    • Medical Ethics (67)
    • Nephrology (258)
    • Neurology (2146)
    • Nursing (134)
    • Nutrition (338)
    • Obstetrics and Gynecology (427)
    • Occupational and Environmental Health (518)
    • Oncology (1183)
    • Ophthalmology (365)
    • Orthopedics (128)
    • Otolaryngology (220)
    • Pain Medicine (147)
    • Palliative Medicine (50)
    • Pathology (312)
    • Pediatrics (698)
    • Pharmacology and Therapeutics (302)
    • Primary Care Research (267)
    • Psychiatry and Clinical Psychology (2187)
    • Public and Global Health (4672)
    • Radiology and Imaging (781)
    • Rehabilitation Medicine and Physical Therapy (457)
    • Respiratory Medicine (624)
    • Rheumatology (274)
    • Sexual and Reproductive Health (226)
    • Sports Medicine (210)
    • Surgery (252)
    • Toxicology (43)
    • Transplantation (120)
    • Urology (94)